{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:18:09Z","timestamp":1789492689904,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"the National Key R&D Program of China","award":["grant no. 2022YFB4702904"],"award-info":[{"award-number":["grant no. 2022YFB4702904"]}]},{"name":"the Technical Innovation foundation for clinical medicine by Jinan scientific and technical bureau","award":["grant no. 202430048"],"award-info":[{"award-number":["grant no. 202430048"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To estimate the efficacy of intravitreal injection (IVI) versus subretinal injection (SRI) of tissue plasminogen activator in the treatment of submacular hemorrhage (SMH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted in six major data sets from inception to 31 October 2025. Random effects meta-analysis was performed to evaluate the final best-corrected visual acuity (BCVA, logMAR) and the changes in central retinal thickness (CRT, \u03bcm), and the risk ratio of complete displacement of hemorrhage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of seven studies on 353 eyes were finally included. Best-corrected visual acuity was similar between the IVI and SRI groups at 1 month and 6 months postoperation, while better in the IVI group 3 months postoperatively. The final CRT was similar between the two groups. There were no statistical differences between the two groups in the RRs of complete displacement of hemorrhage, total adverse events, recurrent SMH, increased intraocular pressure, postoperative retinal detachment, and vitreous hemorrhages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The IVI group showed a better BCVA at 3 months, the two groups showed comparable results in the recovery of BCVA, CRT, and complete hemorrhage displacement at the final visit (within 6 months).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004774","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:00:23Z","timestamp":1769025623000},"page":"819-828","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["COMPARABLE RESULTS OF SUBRETINAL INJECTION AND INTRAVITREAL INJECTION OF TISSUE PLASMINOGEN ACTIVATOR IN THE TREATMENT OF SUBMACULAR HEMORRHAGE"],"prefix":"10.1097","volume":"46","author":[{"given":"Lu","family":"Zhang","sequence":"first","affiliation":[{"name":"Ophthalmic Center of Shandong University, The Second Qilu Hospital of Shandong University, Shandong, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Operation Room, The Second Qilu Hospital of Shandong University, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Si","sequence":"additional","affiliation":[{"name":"Ophthalmic Center of Shandong University, The Second Qilu Hospital of Shandong University, Shandong, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Ophthalmic Center of Shandong University, The Second Qilu Hospital of Shandong University, Shandong, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Ophthalmic Center of Shandong University, The Second Qilu Hospital of Shandong University, Shandong, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Qin","sequence":"additional","affiliation":[{"name":"Ophthalmic Center of Shandong University, The Second Qilu Hospital of Shandong University, Shandong, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"R2-20260915","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00417-022-05922-0","article-title":"Simultaneous intravitreal aflibercept and gas injections for submacular hemorrhage secondary to polypoidal choroidal vasculopathy","volume":"261","author":"Wakabayashi","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"e706","DOI":"10.1111\/aos.14676","article-title":"Massive submacular haemorrhage in polypoidal choroidal vasculopathy versus typical neovascular age-related macular degeneration","volume":"99","author":"Cho","year":"2021","journal-title":"Acta Ophthalmologica"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0039-6257(97)00089-1","article-title":"Pathophysiology and management of subretinal hemorrhage","volume":"42","author":"Hochman","year":"1997","journal-title":"Surv Ophthalmol"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.2147\/OPTH.S324091","article-title":"Subretinal injection of recombinant tissue plasminogen activator and gas tamponade to displace acute submacular haemorrhages secondary to age-related macular degeneration","volume":"15","author":"Iannetta","year":"2021","journal-title":"OPTH"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/S0161-6420(99)90399-8","article-title":"Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement","volume":"106","author":"Hassan","year":"1999","journal-title":"Ophthalmology"},{"key":"R7-20260915","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40942-020-00228-x","article-title":"Surgical management of submacular hemorrhage due to n-AMD: a comparison of three surgical methods","volume":"6","author":"Grohmann","year":"2020","journal-title":"Int J Retina Vitreous"},{"key":"R8-20260915","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ophtha.2023.04.014","article-title":"Surgery, tissue plasminogen activator, antiangiogenic agents, and ARelated Macular Degeneration Study: a randomized controlled trial for submacular hemorrhage secondary to age-related macular degeneration","volume":"130","author":"Gabrielle","year":"2023","journal-title":"Ophthalmology"},{"key":"R9-20260915","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/IAE.0000000000000954","article-title":"Intravitreal versus subretinal administration of recombinant tissue plasminogen activator combined with gas for acute submacular hemorrhages due to age-related macular degeneration: An Exploratory Prospective Study","volume":"36","author":"de Jong","year":"2016","journal-title":"Retina"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00417-009-1158-7","article-title":"Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator","volume":"248","author":"Hillenkamp","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/IAE.0000000000001030","article-title":"Tissue plasminogen activator for subfoveal hemorrhage due to age-related macular degeneration: comparison of 3 treatment modalities","volume":"36","author":"Fassbender","year":"2016","journal-title":"Retina"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4103\/0301-4738.103779","article-title":"Submacular hemorrhage: a study amongst Indian eyes","volume":"60","author":"Rishi","year":"2012","journal-title":"Indian J Ophthalmol"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s10792-021-01976-x","article-title":"Comparison of subretinal versus intravitreal injection of recombinant tissue plasminogen activator with gas for submacular hemorrhage secondary to wet age-related macular degeneration: treatment outcomes and brief literature review","volume":"41","author":"Tranos","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"The Br J Ophthalmol"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/archopht.1991.01080050139046","article-title":"Fibrin directs early retinal damage after experimental subretinal hemorrhage","volume":"109","author":"Toth","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0161-6420(92)31939-6","article-title":"Tissue plasminogen activator thrombolysis during surgical evacuation of experimental subretinal hemorrhage","volume":"99","author":"Johnson","year":"1992","journal-title":"Ophthalmology"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/S0161-6420(99)90435-9","article-title":"Discussion by wilson J. Heriot, FRACO, FRACS","volume":"106","author":"Heriot","year":"1999","journal-title":"Ophthalmology"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0002-9394(00)00734-0","article-title":"Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid\u2013gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration","volume":"131","author":"Haupert","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0002-9394(14)72259-7","article-title":"Tissue plasminogen activator treatment of experimental subretinal hemorrhage","volume":"111","author":"Lewis","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"R20-20260915","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R22-20260915","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R23-20260915","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ajo.2022.09.008","article-title":"Review of fibrosis in neovascular age-related macular degeneration","volume":"246","author":"Cheong","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"R24-20260915","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40942-019-0200-0","article-title":"Traumatic submacular hemorrhage: available treatment options and synthesis of the literature","volume":"5","author":"Casini","year":"2019","journal-title":"Int J Retina Vitreous"},{"key":"R25-20260915","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.ophtha.2013.11.004","article-title":"Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization","volume":"121","author":"Kim","year":"2014","journal-title":"Ophthalmology"},{"key":"R26-20260915","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.ajo.2014.02.007","article-title":"Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration","volume":"157","author":"Chang","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R27-20260915","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/jcm12031035","article-title":"Efficacy evaluation of tissue plasminogen activator with anti-vascular endothelial growth factor drugs for submacular hemorrhage treatment: a meta-analysis","volume":"12","author":"He","year":"2023","journal-title":"J Clin Med"},{"key":"R28-20260915","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.survophthal.2015.04.004","article-title":"Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature","volume":"61","author":"Stanescu-Segall","year":"2016","journal-title":"Surv Ophthalmol"},{"key":"R29-20260915","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3928\/23258160-20161219-04","article-title":"Intravitreal versus subretinal tissue plasminogen activator injection for submacular hemorrhage","volume":"48","author":"Bell","year":"2017","journal-title":"Ophthalmic Surg lasers Imaging retina"},{"key":"R30-20260915","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/08820538.2011.585368","article-title":"Treatment for submacular hemorrhage associated with neovascular age-related macular degeneration","volume":"26","author":"Shultz","year":"2011","journal-title":"Semin Ophthalmol"},{"key":"R31-20260915","article-title":"Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration","author":"Elsbeth","journal-title":"Ophthalmologica"},{"key":"R32-20260915","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000537939","article-title":"Submacular hemorrhage during neovascular age-related macular degeneration: a meta-analysis and meta-regression on the use of tPA and anti-VEGFs","volume":"247","author":"Veritti","year":"2024","journal-title":"Ophthalmologica"},{"key":"R33-20260915","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/IAE.0000000000004417","article-title":"Rhegmatogenous retinal detachment after vitrectomy and subretinal tissue plasminogen activator for submacular hemorrhage","volume":"45","author":"Safran","year":"2025","journal-title":"Retina"},{"key":"R34-20260915","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3390\/ph16091241","article-title":"Suprachoroidal injection: a novel approach for targeted drug delivery","volume":"16","author":"Wu","year":"2023","journal-title":"Pharmaceuticals"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:00:21Z","timestamp":1789491621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004774"}},"subtitle":["A Meta-Analysis of Efficacy"],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004774","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}